Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

pembrolizumab 185Carboplatin 131Paclitaxel 123Gemcitabine 122Docetaxel 97Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 65Bevacizumab 65Capecitabine 60atezolizumab 55fludarabine 49Fluorouracil 49Azacitidine 49130-nm albumin-bound paclitaxel 43Irinotecan 42venetoclax 41Trastuzumab 41Cetuximab 40Leucovorin 37Ipilimumab 36Erlotinib Hydrochloride 35Oxaliplatin 32Fulvestrant 32Cytarabine 32avelumab 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × talampanel × Clear all
NCT00062504 2011-05-23

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
30 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡